Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy
Completed
Octapharma
Phase 3
2017-09-27
Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients
With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy
Panzyga in CIDP Administered at Different Infusion Rates
Unknown status
Vera Bril
Phase 3
2017-06-01
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral
neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune
globulin), which is infused in a set regimen that requires 4-5 hours in a hospital day unit,
taking up resources such as nursing time and hospital space. Chronic treatment is required in
most cases.
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Not yet recruiting
Octapharma
Phase 3
2021-12-01
Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory
Demyelinating Polyradiculoneuropathy (CIDP) Patients
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
